Bridgewater Associates LP Makes New $638,000 Investment in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Bridgewater Associates LP purchased a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 5,245 shares of the biotechnology company's stock, valued at approximately $638,000.

Several other large investors have also bought and sold shares of the company. World Investment Advisors LLC acquired a new position in Sarepta Therapeutics in the third quarter worth approximately $2,418,000. Tidal Investments LLC grew its stake in Sarepta Therapeutics by 91.2% during the third quarter. Tidal Investments LLC now owns 5,634 shares of the biotechnology company's stock worth $704,000 after buying an additional 2,688 shares during the last quarter. Garden State Investment Advisory Services LLC acquired a new stake in shares of Sarepta Therapeutics in the third quarter valued at $2,115,000. GAMMA Investing LLC lifted its holdings in Sarepta Therapeutics by 27.7% during the 4th quarter. GAMMA Investing LLC now owns 854 shares of the biotechnology company's stock worth $104,000 after buying an additional 185 shares in the last quarter. Finally, Everence Capital Management Inc. bought a new stake in shares of Sarepta Therapeutics during the fourth quarter worth approximately $344,000. Institutional investors own 86.68% of the company's stock.

Sarepta Therapeutics Price Performance

Shares of SRPT stock traded down $0.29 on Friday, reaching $61.48. 400,024 shares of the company were exchanged, compared to its average volume of 1,421,850. Sarepta Therapeutics, Inc. has a 1 year low of $48.01 and a 1 year high of $173.25. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The business has a 50-day moving average price of $78.22 and a 200 day moving average price of $106.20. The company has a market cap of $5.97 billion, a price-to-earnings ratio of 49.18 and a beta of 0.93.

Analyst Ratings Changes

SRPT has been the topic of a number of recent research reports. HC Wainwright reissued a "neutral" rating and issued a $75.00 target price on shares of Sarepta Therapeutics in a research report on Wednesday, April 16th. Scotiabank reduced their price target on Sarepta Therapeutics from $105.00 to $80.00 and set a "sector perform" rating on the stock in a research report on Thursday, March 20th. Piper Sandler lowered their price objective on shares of Sarepta Therapeutics from $182.00 to $110.00 and set an "overweight" rating for the company in a research report on Monday. Royal Bank of Canada downgraded shares of Sarepta Therapeutics from an "outperform" rating to a "sector perform" rating and lowered their price target for the stock from $161.00 to $87.00 in a report on Monday, March 31st. Finally, Needham & Company LLC reduced their price target on Sarepta Therapeutics from $202.00 to $183.00 and set a "buy" rating on the stock in a research report on Thursday, April 3rd. Six investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $158.70.

Insiders Place Their Bets

In related news, Director Claude Nicaise sold 2,491 shares of Sarepta Therapeutics stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total transaction of $248,203.24. Following the sale, the director now directly owns 27,812 shares in the company, valued at $2,771,187.68. This trade represents a 8.22 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 7.70% of the stock is currently owned by insiders.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.